Eleonora Candi
No abstract text is available yet for this article.
January 26, 2021: Hormones & Cancer
Shafaq Khairi, Jenae Osborne, Michelle F Jacobs, Gregory T Clines, Barbra S Miller, David T Hughes, Tobias Else
Primary hyperparathyroidism (pHPT) is associated with familial syndromes such as multiple endocrine neoplasia type 1 (MEN1), 2A (MEN2A), MEN-like syndromes (CDKN1B), and CDC73-related disorder (hyperparathyroidism - jaw tumor syndrome (HPJT)). Familial hypocalciuric hypercalcemia (FHH) caused by CASR variants is an important differential diagnosis for pHPT. In order to evaluate the contribution of hereditary causes to pHPT in patients encountered in a specialized clinic, we conducted a retrospective study on patients with pHPT that underwent germline genetic testing...
October 2020: Hormones & Cancer
Laura MacDonald, Jonathan Jenkins, Grace Purvis, Joshua Lee, Aime T Franco
Thyroid cancer is the most common endocrine malignancy and incidences are rising rapidly, in both pediatric and adult populations. Many thyroid tumors are successfully treated which results in low mortality rates, but there is often a significant morbidity associated with thyroid cancer treatments. For patients with tumors that are not successfully treated with surgical resection or radioactive iodine treatment, prognosis is dramatically reduced. Patients diagnosed with anaplastic thyroid cancer face a very grim prognosis with a median survival of 6 months post-diagnosis...
October 2020: Hormones & Cancer
Jeanne P Uyisenga, Yvan Butera, Ahmed Debit, Claire Josse, Costas C Ainhoa, Emile Karinganire, Aimee P Cyuzuzo, Nicole Umurungi, Yves Kalinijabo, Simeon Uwimana, Leon Mutesa, Vincent Bours
Breast cancer is a complex disease, and it is the most common cause of morbidity and mortality among women worldwide. In Sub-Saharan Africa, the clinical characteristics and tumor profiles of breast cancer are still unknown. In the present study we aimed to determine breast tumor profiles of the Rwandan patients in relation to age and tumor stages. We compare our findings to related results from other sub-Saharan Africa studies. Data on age at diagnosis, tumor stage, and hormonal profiles of 138 patients diagnosed between January 2015 and December 2018 were retrospectively retrieved from electronic medical records at three referral hospitals in Rwanda...
August 9, 2020: Hormones & Cancer
Robert Dembinski, Vishnu Prasath, Carisa Bohnak, Charalampos Siotos, Mohamad E Sebai, Kevin Psoter, Faiz Gani, Joe Canner, Melissa S Camp, Armina Azizi, Lisa Jacobs, Mehran Habibi
ER+/PR- (estrogen receptor positive and progesterone receptor negative) tumors constitute only a small portion of the breast cancer population. Patients with ER+/PR- tumors, however, are characterized by worse survival compared to patients with ER+/PR+ (estrogen receptor positive and progesterone receptor positive) tumors. Controversy exists regarding the efficacy of hormone blocking therapy for patients with ER+/PR- tumors. The NCDB was queried between 2004 and 2015, and patients with invasive ER+/PR- tumors were identified...
August 2020: Hormones & Cancer
Carolina Fernández-Trujillo, Julio Pérez-Zaballos, Carlos A Rodríguez-Pérez, Yaiza López-Plasencia, Dunia Marrero-Arencibia, Juan J Cabrera-Galván, Mauro Boronat
Fine needle aspiration biopsy does not permit to distinguish between benign and malignant follicular thyroid lesions (category IV in the Bethesda Cytopathology System). Some reports have suggested an association between increased serum TSH levels and thyroid cancer, so the aim of this study was to investigate the association between TSH levels and malignancy in patients with follicular thyroid nodules. Therefore, we conducted a retrospective study of all subjects who underwent surgical treatment for Bethesda IV thyroid nodules in a single center (years 2012-2017)...
August 2020: Hormones & Cancer
Santiago Madera, María F Chervo, Violeta A Chiauzzi, Matías G Pereyra, Leandro Venturutti, Franco Izzo, Agustina Roldán Deamicis, Pablo Guzman, Agustina Dupont, Juan Carlos Roa, Mauro E Cenciarini, Sabrina Barchuk, Silvina Figurelli, Daniel Lopez Della Vecchia, Claudio Levit, Gabriel Lebersztein, Fabiana Anfuso, Teresa Castiglioni, Eduardo Cortese, Sandra Ares, Ernesto Gil Deza, Felipe G Gercovich, Cecilia J Proietti, Roxana Schillaci, Rosalía I Cordo Russo, Patricia V Elizalde
The hormone receptor-positive (estrogen and/or progesterone receptor (PR)-positive) and HER2-negative breast cancer (BC) subtype is a biologically heterogeneous entity that includes luminal A-like (LumA-like) and luminal B-like (LumB-like) subtypes. Decreased PR levels is a distinctive biological feature of LumB-like tumors. These tumors also show reduced sensitivity to endocrine therapies and poorer prognosis than LumA-like tumors. Identification of biomarkers to accurately predict disease relapse in these subtypes is crucial in order to select effective therapies...
July 6, 2020: Hormones & Cancer
David K Lung, Rebecca M Reese, Elaine T Alarid
Transcriptional regulation of ESR1, the gene that encodes for estrogen receptor α (ER), is critical for regulating the downstream effects of the estrogen signaling pathway in breast cancer such as cell growth. ESR1 is a large and complex gene that is regulated by multiple regulatory elements, which has complicated our understanding of how ESR1 expression is controlled in the context of breast cancer. Early studies characterized the genomic structure of ESR1 with subsequent studies focused on identifying intrinsic (chromatin environment, transcription factors, signaling pathways) and extrinsic (tumor microenvironment, secreted factors) mechanisms that impact ESR1 gene expression...
June 26, 2020: Hormones & Cancer
Siddharth Gupta, Thanakorn Pungsrinont, Ondrej Ženata, Laura Neubert, Radim Vrzal, Aria Baniahmad
Prostate cancer (PCa) is the most common cancer and the second leading cause of cancer-related deaths of men in Western countries. Androgen deprivation therapy is initially successful, however eventually fails, and tumors progress to the more aggressive castration-resistant PCa (CRPC). Yet, androgen receptor (AR) usually remains as a major regulator of tumor cell proliferation in CRPC. Interleukin-23 (IL-23) was recently shown to promote the development of CRPC by driving AR transcription. Here we used the androgen-sensitive LNCaP, castration-resistant C4-2, and 22Rv1 cells...
June 20, 2020: Hormones & Cancer
Rubí Viedma-Rodríguez, María Guadalupe Martínez-Hernández, Dante Israel Martínez-Torres, Luis Arturo Baiza-Gutman
The development of breast cancer (BC) is influenced by age, overweight, obesity, metabolic syndrome, and diabetes mellitus (DM), which are associated with hyperglycemia, glucose intolerance, insulin resistance, and oxidative stress. High glucose concentration increases a metastatic phenotype in cultured breast cancer cells, promoting cell proliferation, reactive species production (ROS), epithelial mesenchymal transition (EMT), and expression of proteolytic enzymes. Our aim was to determine whether diabetes mellitus favor BC progression in mice and its association with changes in the content of ROS and glycolytic and proteolytic enzymes...
June 16, 2020: Hormones & Cancer
Priscilla Ming Yi Lee, Chi Hei Kwok, Wing Cheong Chan, Cherry Wu, Koon-Ho Tsang, Sze-Hong Law, Yiu-Cheong Yeung, Feng Wang, Xiaohong R Yang, Lap Ah Tse
Previous studies reported heterogeneous associations between obesity and reproductive-related breast cancer risk factors and breast cancer intrinsic subtypes; however, few studies have been conducted in Asian populations. Here, we aimed to examine whether risks associated with established breast cancer risk factors varied by breast cancer subtypes in Chinese women. We conducted a hospital-based case-control study in Hong Kong, including a total of 2169 Chinese women. Unconditional polytomous logistic regression models were used to calculate adjusted odds ratios (AORs) and 95% confidence intervals(95%CIs) to estimate relative risks associated with examined risk factors in case-control analyses and to test for heterogeneity across breast cancer subtypes in case-case analyses...
June 3, 2020: Hormones & Cancer
Luke Ardolino, Aaron Hansen, Stephen Ackland, Anthony Joshua
Advanced adrenocortical cancer (ACC) is a rare, highly aggressive malignancy, which typically has a poor prognosis. In advanced ACC, the overall trend is toward a short PFS interval following first-line systemic therapy, highlighting a clear need for improved second-/third-line treatment strategies. We conducted a review of the literature and relevant scientific guidelines related to systemic therapy for advanced ACC. Public indexes including PubMed/MEDLINE were searched. Treatment selection in the second-line setting is based on small phase 2 trials, case reports, and pre-clinical evidence...
April 17, 2020: Hormones & Cancer
Aida Orois, Celia Badenas, Jordi L Reverter, Verónica López, Miriam Potrony, Mireia Mora, Irene Halperin, Josep Oriola
To date, the genes involved in familial non-medullary thyroid cancer (FNMTC) remain poorly understood, with the exception of syndromic cases of FNMTC. It has been proposed that germline mutations in telomere-related genes, such as POT1, described in familial melanoma might also predispose individuals to thyroid cancer, requiring further research. We aimed to identify germline mutations in POT1 in selected FNMTC families (with at least three affected members) without a history of other cancers or other features, and to describe the clinical characteristics of these families...
April 2020: Hormones & Cancer
Julia R Austin, Brenna J Kirkpatrick, Rocío Rivera Rodríguez, Michael E Johnson, Daniel D Lantvit, Joanna E Burdette
While flavonoids have been studied extensively for estrogen receptor activity, they have not been well studied for their ability to modify progesterone receptor (PR) and glucocorticoid receptor (GR) signaling. Three flavonoid compounds, tangeretin, wogonin, and baicalein, were selected for testing for PR and GR activity based on their structural similarity to known phytoprogesterone-like compounds. Each compound was docked in the binding pocket of PR and GR. Of these compounds, baicalein was predicted to be most likely to bind to both receptors...
March 7, 2020: Hormones & Cancer
Aylin Del Moral-Morales, Juan Carlos González-Orozco, José Moisés Capetillo-Velázquez, Ana Gabriela Piña-Medina, Ignacio Camacho-Arroyo
Glioblastomas (GBM) are the most frequent and aggressive primary tumor of the central nervous system. In recent years, it has been proposed that sex hormones such as progesterone play an essential role in GBM biology. Membrane progesterone receptors (mPRs) are a group of G protein-coupled receptors with a wide distribution and multiple functions in the organism. There are five mPRs subtypes described in humans: mPRα, mPRβ, mPRγ, mPRδ, and mPRε. It has been reported that human-derived GBM cells express the mPRα, mPRβ, and mPRγ subtypes, and that progesterone promotes GBM progression in part by mPRα specific activation; however, it is still unknown if mPRδ and mPRε are also expressed in this type of tumor cells...
February 20, 2020: Hormones & Cancer
Yu Pan, Xiuli Wang, Yanzhi Zhang, Juanjuan Qiao, Hironobu Sasano, Keely McNamara, Baoshan Zhao, Dongmei Zhang, Yuhua Fan, Lili Liu, Xueling Jia, Ming Liu, Sihang Song, Lin Wang
Proline-, glutamic acid-, leucine-rich protein 1 (PELP1) is a novel estrogen receptor (ER) coregulator, demonstrated distinctive characters from other ERα coregulators, and has been suggested to be involved in metastasis of several cancers. In ERα-positive breast cancer, PELP1 overexpression enhanced ruffles and filopodium-like structure stimulated by estradiol (E2 ) through extranuclear cell signaling transduction hereby increased cell motility. However, whether PELP1 is also involved in extracellular matrix remodeling of ERα-positive breast cancer cells is still unknown...
February 10, 2020: Hormones & Cancer
Neeraja Sathyamoorthy, Carol A Lange
No abstract text is available yet for this article.
February 2020: Hormones & Cancer
Emily Smart, Luis H Alejo, Jonna Frasor
There is a desperate need in the field for mouse mammary tumors and cell lines that faithfully mimic estrogen receptor (ER) expression and activity found in human breast cancers. We found that several mouse mammary cancer cell lines express ER but fail to demonstrate classical estrogen-driven proliferation or transcriptional activity. We investigated whether these cell lines may be used to model tamoxifen resistance by using small molecule inhibitors to signaling pathways known to contribute to resistance. We found that the combination of NFκB inhibition and ER antagonists significantly reduced cell proliferation in vitro, as well as growth of syngeneic tumors...
February 1, 2020: Hormones & Cancer
Namita Ganesh Hattangady, Jessica Foster, Antonio Marcondes Lerario, Daniela Ponce-Balbuena, Juilee Rege, Silvia Monticone, William E Rainey, Paolo Mulatero, Tobias Else
Primary aldosteronism (PA) is the most common cause of secondary hypertension with a high prevalence among patients with resistant hypertension. Despite the recent discovery of somatic variants in aldosterone-producing adenoma (APA)-associated PA, causes for PA due to bilateral aldosterone production (bilateral hyperaldosteronism; BHA) remain unknown. Herein, we identified rare gene variants in ATP2B4, in a cohort of patients with BHA. ATP2B4 belongs to the same family of Ca-ATPases as ATP2B3, which is involved in the pathogenesis of APA...
January 30, 2020: Hormones & Cancer
Amy M Fowler, Kelley Salem, Michael DeGrave, Irene M Ong, Shane Rassman, Ginny L Powers, Manoj Kumar, Ciara J Michel, Aparna M Mahajan
Tumor mutations in the gene encoding estrogen receptor alpha (ESR1) have been identified in metastatic breast cancer patients with endocrine therapy resistance. However, relatively little is known about the occurrence of mutations in the progesterone receptor (PGR) gene in this population. The study objective was to determine the frequency and prognostic significance of tumor PGR mutations for patients with estrogen receptor (ER)-positive metastatic breast cancer. Thirty-five women with metastatic or locally recurrent ER+ breast cancer were included in this IRB-approved, retrospective study...
January 16, 2020: Hormones & Cancer
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.